CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, ImClone Systems, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Curran — Professor and Chairman, Department of Radiation Oncology; Deputy Director for Clinical Sciences, Kimmel Cancer Center of Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genmab, ImClone Systems, OSI Pharmaceuticals Inc. Dr Greco — Medical Director, Sarah Cannon Cancer Center, Nashville, Tennessee. Consulting Fees: Bristol-Myers Squibb Company, Eli Lilly and Company; Contracted Research: Ascenta Therapeutics Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology. Dr Hanna — Associate Professor, Department of Medicine, Division of Hematology/Oncology, School of Medicine, Indiana University Medical Center, Indianapolis, Indiana. Consulting Fees: Bayer Pharmaceuticals Corporation, Eli Lilly and Company; Contracted Research: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Onyx Pharmaceuticals Inc. Dr Kim — Assistant Professor of Medicine, Department of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Consulting Fees: Genentech BioOncology, ImClone Systems, OSI Pharmaceuticals Inc, Sanofi-Aventis; Contracted Research: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Sanofi-Aventis. Dr Langer — Medical Director of Thoracic Oncology, Fox Chase Cancer Center; Vice Chair, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania. Consulting Fees: Amgen Inc, Ardea Biosciences Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmacyclics Inc, Sanofi-Aventis; Contracted Research: Active Biotech AB, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics Inc, Eli Lilly and Company, Genentech BioOncology, MedImmune Inc, Millennium Pharmaceuticals Inc, Ortho Biotech Products LP, Pfizer Inc, Sanofi-Aventis, Schering-Plough Corporation, Vertex Pharmaceuticals Incorporated; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Ortho Biotech Products LP, Sanofi-Aventis. Dr Lynch — Chief, Hematology Oncology; Director, MGH Thoracic Oncology Center; Associate Professor of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Consulting Fees: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Millennium Pharmaceuticals Inc, OSI Pharmaceuticals Inc, Sanofi-Aventis. Dr Miller — Associate Attending Physician, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York. Consulting Fees: Boehringer Ingelheim GmbH, Eli Lilly and Company, Exelixis Inc, Genentech BioOncology; Royalty: MolecularMD. Dr Pass — Professor of Cardiothoracic Surgery and Surgery; Chief, Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU School of Medicine and NCI Cancer Center, New York, New York. No financial interests or affiliations to disclose. Dr Sandler — Associate Professor of Medicine; Medical Director, Thoracic Oncology; Director, Vanderbilt-Ingram Cancer Center Affiliate Network Program, Vanderbilt University Medical Center, Division of Hematology/Oncology, Nashville, Tennessee. Consulting Fees: AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis, Wyeth; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech BioOncology. Dr Schiller — Professor and Division Chief, Hematology/Oncology; Deputy Director, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, OSI Pharmaceuticals Inc, Sanofi-Aventis; Contracted Research: Genentech BioOncology. Dr Socinski — Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Eli Lilly and Company, Genentech BioOncology, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.